The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/183291
Exclusive Life Science Feature "When you have a market value of $29 million and you are running out of money, you had better start changing the culture of the enterprise." Leonard Jacob, M.D., Ph.D. closing a facility, minimized the loss of jobs, and allowed Antares to jettison a cultural integration challenge. With that behind them, leadership could then focus on putting more support behind the Minnesota device area, which was producing patents around autoinjectors and needle-free injectors. To do this, the company needed more revenue and sought to develop some strategic partners, which required the chairman and CEO to work hand in glove. For example, Wotton and Jacob met with the CEO of Teva North America over dinner. In 2009, Teva (NYSE: TEVA) received FDA approval to market the Antares needle-free injector with the hGH product in the U.S. Antares also created partnerships with the biggest of Big Pharma, Pfizer (NYSE: PFE), in 2011, as well as another top 50 pharma company, Actavis (NYSE: ACT), formerly Watson Pharmaceuticals. Antares continues to expand its IP portfolio with 43 patents filed and 9 patents issued in the past 18 months. It also has two potential blockbusters in the works -- OTREXUP, a patented autoinjection system that works in combination with methotrexate to help rheumatoid arthritis (RA) sufferers, and a combination testosterone drug-delivery system for hypogonadism. OTREXUP is currently under FDA review with a potential approval as early as October; the second drug has entered clinical trials. The Antares model is to take generic drugs and link them to a patentprotected device system with a clear safety or efficacy benefit. This model builds extensions through a product's life cycle, creating additional exclusivity. With a market cap of just over half a billion dollars, Antares has analysts like The Motley Fool taking notice of its successful turnaround -- something Chairman of the Board Jacob describes as less of a science and more of an art. We deliver more val-ue noun / 'val-(,)yü / 1: A fair return or equivalent in goods, services, or money for something exchanged 2: A recent Industry Standard Research report highlighted LabCorp Clinical Trials as one of the top global central laboratories. Sponsors perceived that LabCorp offered the highest overall value among central labs while meeting customer expectations on price. LabCorp was also the only central lab to meet or exceed client expectations across all key service attributes. Furthermore, the report showed that LabCorp's top service attributes as rated by customers were "high value", "broad test menu", "geographic coverage" and "quality". Visit our website to learn more about LabCorp's extensive service portfolio as a global leader in biomarker testing. labcorp.com/clinicaltrials October 2013 LifeScienceLeader.com 41